ArticleBlood neoplasia2025
Characterization of fusion transcripts in AML without recurrent genetic abnormalities unravels new putative fusion genes.
Article in Blood neoplasia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the last few years, whole-transcriptome sequencing has shown a high number of low-frequency fusion transcripts (FTs) involved in acute myeloid leukemia (AML) pathogenesis. Most of them are not identifiable through conventional diagnostic techniques. In this research, using RNA sequencing, we have investigated FTs in 109 cases of AML without recurrent genetic abnormalities (as defined by the fourth edition of the World Health Organization Classification of Hematolymphoid Tumours). We identified and validated 6 well-known AML-causing FTs (Tier-1), 9 FTs in which recurrently affected genes in AML were involved (Tier-2), and 4 Tier-3 FTs, along with other FTs found in healthy tissue databases (Tier-4). We highlighted 2 previously unknown FTs (
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.